Intellipharmaceutics Cautions Over Financial Future

Controlled-release and targeted-release oral solids specialist Intellipharmaceutics has offered a sober summary of its finances in the wake of a US Food and Drug Administration committee decision recommending that the agency not approve the firm’s Aximris XR (oxycodone hydrochloride) extended-release tablets, highlighting significant financial uncertainty over the future of its business.

In January, the FDA’s anesthetic and analgesic drug products advisory committee and drug safety and risk management advisory committee voted...